Barts Endocarditis Research Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16+
SponsorQueen Mary University of London
About this trial
The Barts Endocarditis Research Registry is being set up to give a unique opportunity to assess the characteristics of Infective Endocarditis (IE) in our population cohort, the current use of imaging techniques, as well as the implementation of the ESC guidelines and its consequence in terms of prognosis. All this will help improve the diagnosis and management of IE. The registry will also form the core of all our subsequent work, including interventional studies. The endocarditis research registry is to record the epidemiological, demographic, microbiological, surgical and outcome data in our cohort of endocarditis patients. This work will underpin all future work in endocarditis by clearly defining our patient cohort and the outcomes from treatment. We have a series of studies planned that we believe will influence the management of endocarditis (we are working up proposals for genomic and therapeutic trials that will subsequently be presented for ethical and hospital approval). The registry will be generic to all our planned studies, and will allow us to capture data to assess treatment effectiveness
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
• Patients aged 16 and over (Patients under 16 years of age are not admitted to Barts Heart Centre)
Patients admitted to Barts Heart Centre with confirmed Endocarditis (see above)
Patients attending outpatients with confirmed/suspected Endocarditis
Patients with possible IE who complete treatment for endocarditis
Disqualifiers
• Patients with pacemaker pocket infection with no evidence of pacemaker lead or valve infection
Patients who refuse consent to be included in the research database
Patients with "rejected" endocarditis
Trial population
There are approximately 150 cases of endocarditis each year treated within the trust and recruitment is expected to be rapid
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
registry
Other interventionThis is registry for Infective Endocarditis
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
To define current mortality rates for patients treated for endocarditis at Barts Heart Centre
The primary goal of the endocarditis registry is to record the epidemiological, demographic, microbiological, surgical and outcome data in our cohort of endocarditis patients. This work will underpin all future work in endocarditis by clearly defining our patient cohort and the outcomes from treatment.
Time frame
10 years2
To define current morbidity rates for patients treated for endocarditis at Barts Heart Centre
The primary goal of the endocarditis registry is to record the epidemiological, demographic, microbiological, surgical and outcome data in our cohort of endocarditis patients. This work will underpin all future work in endocarditis by clearly defining our patient cohort and the outcomes from treatment.
Time frame
10 years3
To define current rates of reinfection for patients treated for endocarditis at Barts Heart Centre
The primary goal of the endocarditis registry is to record the epidemiological, demographic, microbiological, surgical and outcome data in our cohort of endocarditis patients. This work will underpin all future work in endocarditis by clearly defining our patient cohort and the outcomes from treatment.
Time frame
10 years4
To define current rates of relapse for patients treated for endocarditis at Barts Heart Centre
The primary goal of the endocarditis registry is to record the epidemiological, demographic, microbiological, surgical and outcome data in our cohort of endocarditis patients. This work will underpin all future work in endocarditis by clearly defining our patient cohort and the outcomes from treatment.
Time frame
10 yearsSecondary outcomes
1
To collect data regarding infecting organism, valve appearances and pathological markers and investigate their relationship to mortality, morbidity, reinfection and relapse rates
A secondary aim will be to use the registry to develop a series of observational studies, especially how the infecting organism interacts with the diagnostic indices in our labs and imaging protocols
Time frame
10 years2
To collect data regarding infecting organism and investigate its relationship to mortality, morbidity, reinfection and relapse rates
A secondary aim will be to use the registry to develop a series of observational studies, especially how the infecting organism interacts with the diagnostic indices in our labs and imaging protocols
Time frame
10 years3
To collect data regarding valve appearance and investigate its relationship to mortality, morbidity, reinfection and relapse rates
A secondary aim will be to use the registry to develop a series of observational studies, especially how the infecting organism interacts with the diagnostic indices in our labs and imaging protocols
Time frame
10 years4
To collect data regarding pathological markers and investigate its relationship to mortality, morbidity, reinfection and relapse rates
A secondary aim will be to use the registry to develop a series of observational studies, especially how the infecting organism interacts with the diagnostic indices in our labs and imaging protocols
Time frame
10 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov